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The vaccinia virus E3L gene product, pE3, is a dsRNA binding protein that prevents activation of the interferon-induced,
dsRNA-activated protein kinase, PKR. Activation of PKR, which results in phosphorylation of the translation initiation factor,
eIF2a, leads to the inhibition of protein synthesis, a process involved in defense against virus infection. The E3L gene product
has a conserved dsRNA binding domain (DRBD) in its carboxyl-terminal region and has been shown to function in vitro by
sequestration of dsRNA. We have utilized in vitro binding assays and the yeast two-hybrid system to demonstrate direct
interactions of pE3 with PKR. By these methods, we demonstrate that pE3 interacts with two distinct regions in PKR, the
amino-terminal (amino acids 1–99) located in the regulatory domain and the carboxyl-terminal (amino acids 367–523) located
in the catalytic domain. The amino-terminal region of PKR that interacts with pE3 contains a conserved DRBD, suggesting that
PKR can form nonfunctional heterodimers with pE3, analogous to those seen with other dsRNA binding proteins. Interaction
of pE3 with the amino-terminal region of PKR is enhanced by dsRNA. In contrast, dsRNA reduces the interaction of pE3 with
the carboxyl-terminal region of PKR. Competition experiments demonstrate that the carboxyl-terminal region of PKR, to which
pE3 binds, overlaps the region with which eIF2a and the pseudosubstrate pK3 interact, suggesting that pE3 may also prevent
PKR activation by masking the substrate binding domain. Like pE3, the amino-terminal region of PKR also interacts with the
carboxyl-terminal domain of PKR. These interactions increase our understanding of the mechanisms by which pE3 down-
regulates PKR. In addition, the PKR–PKR interactions observed leads us to suggest a novel autoregulatory mechanism for
activation of PKR in which dsRNA binding to the DRBD(s) induces a conformational change that results in release of the amino
terminal region from the substrate binding domain, allowing access to eIF2a and its subsequent phosphorylation. © 1998
Academic Press
INTRODUCTION
The interferon-induced, dsRNA-dependent serine/
threonine protein kinase, PKR,3 contributes significantly
to the establishment of the antiviral state by interferon
(Katze, 1995; Mathews, 1996; Samuel et al., 1997). PKR
regulates the initiation of protein synthesis through phos-
phorylation of the a subunit of the protein synthesis
initiation factor eIF2 (Clemens, 1996; DeHaro, 1996; Cle-
mens and Elia, 1997; Samuel et al., 1997). PKR levels are
upregulated by interferon although the kinase is ex-
pressed constitutively by many cell types (Clemens and
Elia, 1997; Samuel et al., 1997). PKR is activated in vitro
and in virus-infected cells by dsRNA (Mathews, 1996;
Clemens and Elia, 1997; Samuel et al., 1997), the binding
of which activates PKR, leading to a conformational
change, autophosphorylation, and the formation of a
homodimeric state (Galabru and Hovanessian, 1987; Co-
sentino et al., 1995; Patel et al., 1995; Wu and Kaufman,
1996; Carpick et al., 1997). The dsRNA binding domain of
PKR maps to the amino-terminal 170 amino acids (Katze
et al., 1991; Feng et al., 1992; Green and Mathews, 1992;
McCormack, et al., 1992; Patel and Sen, 1992). This
region contains two copies of a 65-amino-acid dsRNA
binding motif, rich in basic amino acids, separated by a
short spacer. Such motifs have been found in a number
of modular dsRNA-binding proteins that exhibit diverse
functions (St. Johnson et al., 1992; Bycroft et al., 1995;
Kharrat et al., 1995). These include the Drosophila
staufen protein, Escherichia coli RNase III, and dsRNA-
adenosine deaminases (St. Johnson et al., 1992; Kim et
al., 1994; Kharrat et al., 1995; O’Connell et al., 1995). The
two motifs in PKR have been termed DRBD1 (amino
acids 10–75) and DRBD2 (amino acids 100–165), al-
though the consensus sequences within these motifs
run from residues 55–75 and 145–165 (Green and
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Mathews, 1992; McCormack, et al., 1992). DRBD1 more
closely matches the dsRNA binding motif consensus
sequence and has been shown to be necessary and
sufficient for dsRNA binding (McCormack et al., 1994;
McMillan et al., 1995; Schmedt et al., 1995; Patel et al.,
1996). Both activation and dimerization are mediated
through the dsRNA binding regions (Cosentino et al.,
1995; Patel et al., 1995, 1996; Ortega et al., 1996; Wu and
Kaufman, 1996). However, dimerization between these
domains may occur via protein–protein interaction(s) as
well as via interaction with dsRNA (Patel et al., 1996; Wu
and Kaufman, 1996). A truncated form of PKR represent-
ing amino acids 228–551 [des-(1–227)-PKR], is constitu-
tively active (Wu and Kaufman, 1997). This observation
has led to the proposition that the dsRNA binding do-
mains serve to inhibit the activity of PKR and that dsRNA
binding induces a conformational change that exposes
the dimerization and autophosphorylation sites, leading
to PKR activation (Taylor et al., 1996; Carpick et al., 1997;
Wu and Kaufman, 1997).
Like many eukaryotic protein kinases, PKR is subject
to several layers of cellular regulation including tran-
scriptional activation (Tanaka and Samuel, 1994; Samuel
and Ozata, 1996), association with cellular regulators
(Lee and Katze, 1993; Ito et al., 1994; Lee et al., 1994;
Polyak et al., 1996), and phosphorylation by other ki-
nases (Taylor et al., 1996). In addition, PKR is a target for
regulation by virally encoded inhibitory molecules (Katze,
1993; Jagus and Gray, 1994; Mathews, 1996), reflecting
the fact that the susceptibility of a virus to the antiviral
effects of interferon appears to correlate inversely with
its ability to downregulate PKR (Meurs et al., 1992; Beat-
tie et al., 1995a,b). Vaccinia virus contains two genes,
E3L and K3L, that are expressed early in vaccinia virus
infection and that encode products able to downregulate
PKR activity (Carroll et al., 1993; Davies et al., 1992, 1993).
Consistent with their ability to downregulate PKR, the
products of the E3L and K3L genes contribute to the
ability of vaccinia virus to multiply in interferon-treated
cells (Beattie et al., 1991, 1995a,b; Jagus and Gray, 1994;
Chang et al., 1995).
The E3L gene encodes a polypeptide of 190 amino
acids (25 kDa) that contains one copy of a conserved
DRBD and is thus a member of the same dsRNA binding
protein family as PKR (Chang et al., 1992; Chang and
Jacobs, 1993; Jacobs and Langland, 1996). The dsRNA
binding domain of pE3 lies in the carboxyl-terminal re-
gion of the protein, running from amino acids 118–186
(Chang and Jacobs, 1993; Ho and Shuman, 1996a,b). The
E3L gene product corresponds to the activity found in
vaccinia virus-infected cells described as specific kinase
inhibitory factor (SKIF) (Whitaker-Dowling and Youngner,
1984; Akkaraju et al., 1989). pE3 functions in vitro as a
dsRNA binding protein to sequester the dsRNA and
downregulate PKR with a potency similar to that of pK3
(Akkaraju et al., 1989; Chang et al., 1992; Chang and
Jacobs, 1993; Jagus and Gray, 1994; Ho and Shuman,
1996b). Furthermore, transient expression of the E3L
gene in vivo stimulates translational expression of a
reporter gene and reduces eIF-2a phosphorylation (Da-
vies et al., 1993). In addition, expression of pE3 is able to
inhibit the dsRNA-dependent 29-59 oligoadenylate arm of
the interferon induced host defense pathway (Rivas et
al., 1998). The involvement of pE3 in the downregulation
of host defense mechanisms during vaccinia virus infec-
tion is supported by the findings that pE3 accumulates
early in vaccinia virus infection (Beattie et al., 1995a;
Jagus and Gray, 1994) and that E3L deletion mutants of
vaccinia virus are less able to grow in interferon-treated
cells (Beattie et al., 1995a; Chang et al., 1995). In vaccinia
virus devoid of the E3L gene, resistance to interferon can
be restored by the expression of E3L as a transgene
(Chang et al., 1995) or by the ectopic expression of other
dsRNA binding proteins such as the reovirus s3 protein
(Beattie et al., 1995b), rotavirus NSP3 (Langland et al.,
1994), TRBP (Park et al., 1994), or E. coli RNase III (Shors
and Jacobs, 1997). The complementation data demon-
strate that the dsRNA binding property of pE3 must be
retained for the protein to restore interferon resistance to
vaccinia virus (Shors et al., 1997).
The HIV TAR-RNA binding protein (TRBP), like pE3 can
function to bind dsRNA. TRBP can also interact with the
dsRNA binding region of PKR to form heterodimers and
inhibit PKR activity (Benkirane et al., 1997; Cosentino et
al., 1995). To determine whether pE3 has a similar capa-
bility and to extend our understanding of the mecha-
nism(s) of vaccinia virus-mediated inhibition of PKR, we
have undertaken a structural analysis to determine the
regions within PKR with which pE3 interacts. Using both
in vitro and in vivo binding assays, we have identified two
regions within PKR that bind to pE3, one of which in-
volves the dsRNA binding region of PKR and another that
overlaps the region of interaction with the substrate
eIF2a and the pseudosubstrate, pK3. The interactions of
pE3 with PKR suggest that it can inhibit PKR activity not
only by sequestering dsRNA but also by direct interac-
tion with the regulatory domain of the kinase and/or by
interference with substrate binding. These data extend
our understanding of the mechanism of PKR downregu-
lation by vaccinia virus pE3 and in so doing expand our
understanding of viral strategies that lead to PKR down-
regulation. The surprising interaction of pE3 with the
substrate binding domain of PKR led us to examine
interactions between different domains of PKR itself.
Analogous to the interaction of pE3 with the substrate
binding domain of PKR, the amino-terminal region of PKR
was itself found to interact with the carboxyl-terminal
region in the yeast two-hybrid system. This interaction
suggested a novel intrasteric autoregulatory mechanism
for PKR with dsRNA binding causing a conformational
change and dimerization between the DRBDs of two PKR
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molecules that relieves the masking of the substrate
binding domain of PKR by its own amino-terminal region.
RESULTS
pE3 binds to wild-type PKR in vitro
pE3 has been thought to function primarily as a dsRNA
binding protein (Jagus and Gray, 1994; Jacobs and Lang-
land, 1996; Shors et al., 1997). To determine whether pE3
also has the capacity to interact directly with PKR, like
other dsRNA binding proteins, in vitro binding studies
were performed using immunopurified PKR from HeLa
cells and 35S-labeled pE3. Because a low level of non-
specific binding of 35S-labeled pE3 to mAB-conjugated
Sepharose beads was found to occur, all experiments
included a control without PKR but with the antibody
bound to beads. The nonspecific binding of 35S-labeled
pE3 to PKR mAB linked to beads was not different from
nonspecific binding of 35S-labeled pE3 to goat anti-
mouse IgGs linked to Sepharose beads (data not
shown). Figure 1 presents data showing 35S-labeled pE3
bound to PKR from interferon-treated HeLa cells immo-
bilized on mAB-conjugated Sepharose beads. The re-
sults were compared to a control using the mAB-conju-
gated Sepharose beads only. The bar graph below the
image panel displays radioactive protein bound, ex-
pressed as arbitrary units, as determined using a Storm
840 Phosphoimager. Two forms of the E3L gene product
were produced in the in vitro transcription/translation
reaction both of which bound PKR. The larger product, at
25 kDa, represents the full-length product of the E3L
open reading frame. A smaller polypeptide (20 kDa) is
thought to be the product of translational initiation from
the first AUG downstream from the initiation codon
(Chang et al., 1992; Yuwen et al., 1993). Both forms have
been shown to bind dsRNA (Chang et al., 1992). The
relative level of the smaller polypeptide produced varied
with reticulocyte lysate batch used (data not shown). In
these assays, .95% of PKR in the HeLa extracts bound
to the beads (data not shown) as did 15–20% of 35S-
labeled pE3.
pE3 binds both the regulatory and catalytic domains
of PKR in vitro
To characterize the domains of PKR within which pE3
binds, a series of in vitro binding assays was performed.
35S-labeled pE3 was examined for its ability to interact
with the PKR variants, (Arg296)PKR, PKRD6, PKR1–296,
and PKR242–551, in an in vitro binding assay (Fig. 2). pE3
bound to all four PKR variants. The ability of pE3 to
interact directly with PKR and PKR1–296 is a novel find-
ing but consistent with the homodimerization of PKR and
similar to the heterodimerization of TRBP to PKR through
the dsRNA binding motif(s) (Cosentino et al., 1995; Patel
et al., 1995, 1996; Ortega et al., 1996). However, the
interaction of pE3 with PKR242–551 is surprising and
suggests that downregulation of PKR activity by pE3
FIG. 2. Binding of 35S-labeled pE3 with recombinant PKR variants.
35S-pE3, was synthesized, as described in the legend to Fig. 1, and
incubated with Sepharose beads prebound to the appropriate antibod-
ies (see Materials and Methods), either bound or not bound (beads
only) to the indicated PKR variants. Levels of 35S-labeled protein bound
to mAB–Sepharose (beads only) are shown. Levels of 35S-labeled
protein bound to polyclonal antibody/protein G–Sepharose (beads only)
were similar (data not shown). Radioactive protein bound to the beads
was eluted with SDS–PAGE sample buffer and subjected to SDS–PAGE.
Analysis was as in Fig. 1. INPUT: represents 20% of total 35S-labeled
protein used in each assay.
FIG. 1. Binding of 35S-labeled pE3 to native PKR. 35S-pE3, synthesized
in coupled transcription/translation assays (Promega TNTQuick), was
incubated with anti-PKR mAB–Sepharose beads, either bound, or not
bound (beads only) to HeLa PKR, for 2 h at 4°C with rotation, as
described under Materials and Methods. The beads were rinsed ex-
tensively and bound protein was eluted with SDS–PAGE sample buffer
and subjected to 17.5% SDS–PAGE, using a Tris–Tricine buffer system
(Schagger and von Jagow, 1987). The radiolabeled protein was visual-
ized using a Storm 840 Phosphoimager and quantified with Image-
Quant software. The bar graphs below each image panel indicate the
level of radioactive protein bound.
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through direct interaction might also occur via a mech-
anism distinct from the formation of inactive het-
erodimers with the dsRNA binding regions of PKR or via
dsRNA sequestration. Since PKR242–551 does not bind
dsRNA (Katze et al., 1991; Patel and Sen, 1992), this
interaction must represent a protein–protein interaction.
In contrast, our previous studies using the same PKR
constructs have shown that pK3 binds (Arg296)PKR,
PKRD6 and PKR246–551, but not the amino terminal half
of PKR from amino acids 1–296 (Sharp et al., 1997).
To examine further the molecular determinants within
PKR to which pE3 interacts, an additional set of PKR
variants expressed as fusion proteins with the 26-kDa
glutathione S-transferase were produced; GST-
(Arg296)PKR, GST-PKR1–99, GST-PKR99–551, and GST-
PKR1–523. The production of fusion proteins was verified
by SDS–PAGE and Western blot analysis of cleared cell
extracts using an anti-GST antibody (Fig. 3A). In Fig. 3A,
the arrows denote the positions of the PKR fusion pro-
teins based on their predicted molecular weights.
Smaller polypeptides represent amino-terminal degrada-
tion products. In vitro binding assays using these GST-
fusions and 35S-labeled pE3 were performed (Fig. 3B).
pE3 bound to PKR1–99, consistent with an interaction
through the dsRNA binding motif. However, pE3 did not
bind above control levels to PKR99–551 (Fig. 3B). This is
in contrast to its ability to interact with PKR242–551 as
shown in Fig. 2. This could be explained if the fusion of
the GST binding domain to PKR99–551 interfered with its
interaction with pE3. Alternatively, the recombinant pro-
tein may not fold properly or retain full biological activity.
In summary, pE3 binds in vitro to two regions within PKR;
amino acids 1–99, which encompass the first dsRNA
binding domain of PKR, and a second region from amino
acids 242–523, which covers all of the catalytic subdo-
mains (I-XI) (Meurs et al., 1990).
Competition of 35S-labeled pE3 binding to PKR with
nonlabeled pE3 and pK3
To verify the ability of pE3 to interact with distinct sites
in the amino and carboxy regions of PKR, an excess of
nonlabeled recombinant pE3, pK3, and pK3DGYID were
included in the binding assays (Fig. 4). pE3 was able to
compete with 35S-labeled pE3 for binding to PKR1–296
and PKR242–551. pK3 was also able to compete with
35S-labeled pE3 for binding to PKR242–551 but not with
binding to PKR1–296, suggesting that pE3 binds to a
region in the catalytic domain that is the same, or over-
laps, the substrate binding domain. As a further demon-
stration of the specificity of the interactions of pE3 with
PKR subdomains, the ability of the peptide VKVIRVDYT-
KGYID (Research Genetics, Huntsville, AL) to compete
for the binding of 35S-labeled pE3 was determined. This
peptide corresponds to amino acids 65–78 of pK3, the
region most highly conserved between pK3 and eIF2a
(Goebel et al., 1990). In eIF2a, this region lies 30 amino
acids in a carboxyl-terminal direction from the phosphor-
ylation site and encompasses the molecular determi-
nants recognized by PKR (Kawagishi-Kobayashi et al.,
1997; Sharp et al., 1997). This peptide was able to com-
pete with 35S-labeled pE3 for binding to PKR242–551 but
FIG. 3. Binding of 35S-labeled pE3 to GST-fusion proteins. (A) Western
blot analysis of GST-fusion proteins. BL21 extracts from cells express-
ing GST or the GST-fusion proteins were subjected to 12.5% SDS–PAGE
and transferred to Immobilon-P. Specific GST products were detected
using goat anti-GST polyclonal antibody, followed by rabbit anti-goat
HRP-conjugated antibody. Proteins were visualized using the Amer-
sham ECL kit as per the manufacturer’s recommendations. Arrows
indicate the positions to which GST or GST-fusion proteins should
migrate from their predicted molecular weights. All other bands repre-
sent degradation products. (B) Binding of 35S-labeled pE3 to GST-fusion
proteins: 35S-labeled pE3, synthesized as described in the legend to
Fig. 1, was incubated with GST or the indicated GST–PKR variants
attached to glutathione–Sepharose beads as described under Materi-
als and Methods. Radioactive protein was eluted with SDS–PAGE
sample buffer and subjected to SDS–PAGE. After fractionation by 17.5%
SDS–PAGE, as described in the legend to Fig. 1, the radioactive protein
bound was visualized and quantitated using a Storm 840 Phosphoim-
ager using ImageQuant software. The bar graphs below each image
panel indicate the level of radioactive protein bound in arbitrary units.
INPUT, 40% of total 35S-labeled protein used in each assay.
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not with binding to PKR1–296. The ability of nonlabeled
pK3DGYID to compete for the binding of 35S-labeled pE3
was also determined. In contrast to pK3, pK3DGYID,
which lacks part of the region to which PKR interacts,
was unable to compete with 35S-labeled pE3 for binding
to either PKR truncation product. These results lend
support to the findings that pE3 interacts with the both
the dsRNA binding domain of PKR and with a domain in
the carboxyl-terminus that is the same as, or overlaps
with, the pK3/eIF2a binding site.
Effects of dsRNA on the interaction of 35S-labeled
pE3 binding to PKR
To test the idea that complex formation between pE3
and domains of PKR is dependent on dsRNA binding, the
effects of increasing concentrations of poly(I).poly(C) (0–
200 ng/ml) on the interaction of 35S-labeled pE3 with
wild-type PKR, PKR1–296, and PKR242–551 was deter-
mined (Fig. 5). Binding of 35S-labeled pE3 to all forms of
PKR occurred without the addition of dsRNA. However,
binding of 35S-labeled pE3 to wild-type PKR and PKR1–
242 was stimulated slightly by the inclusion of poly(I-
).poly(C). In contrast, the addition of poly(I).poly(C) re-
duced the interaction of 35S-labeled pE3 with PKR242–
551. Not only does this demonstrate that dsRNA-binding
activity is not required for dimerization of pE3 with the
carboxyl-terminal region, it also suggests that dsRNA will
favor the formation of pE3 homodimers (or heterodimers
with the DRBD of PKR) and thus release of pE3 from the
substrate binding domain.
Interaction of pE3 with PKR in the yeast two-hybrid
system
To substantiate the data obtained from the in vitro bind-
ing analysis, the yeast two-hybrid system was used to
monitor the interactions of pE3 with PKR in vivo (Fields and
Song, 1989; Iwabuchis et al., 1993). In this assay the pro-
teins of interest are expressed as GAL4 DNA-binding or
GAL4 transactivation domain fusion proteins, and their in-
teraction results in the expression of b-galactosidase,
which can be assayed using ONPG as a substrate. As
predicted from the in vitro binding assays (Figs. 2 and 3B),
pE3 interacted with the full length (Arg296)PKR, as well as
PKR1–296 and PKR1–99 in vivo (Table 1). In contrast to the
results from the in vitro binding assays, interaction of pE3
was also detected with PKR99–551. PKR367–551 was also
found to interact with pE3, corroborating the conclusions
from the in vitro binding and competition data. Last, pE3
was shown to undergo homodimerization in vivo, which is
also consistent with in vitro binding data (Ho and Shuman,
1996b). Note that in these experiments, the E3L gene was
expressed in the plasmid containing the GAL4 activation
domain and the PKR sequences were expressed in the
plasmid containing the GAL4 binding domain. The interac-
tion of pE3 with PKR367–551 was not so apparent when the
constructs were expressed from the alternate plasmids
(data not shown).
To provide a positive control and a contrast with the
pE3 data, the interaction of pK3 with PKR and its variants
in the yeast two-hybrid system is also shown (Table 1).
Consistent with previous results (Cosentino et al., 1995;
Craig et al., 1996; Gale et al., 1996), pK3 interacted with
the full-length variant (Arg296)PKR and the carboxyl ter-
minal variants PKR242–551 and PKR367–551 (Craig et al.,
1996; Gale et al., 1996). In contrast, pK3 did not interact
with PKR1–99 or PKR1–296. No evidence for homodimer-
ization of pK3 was detected in this in vivo system.
Interaction of amino- and carboxyl-terminal domains
of PKR in the yeast two-hybrid system
The interaction of pE3 with the carboxyl-terminus of
PKR is surprising. This region of PKR from amino acids
FIG. 4. Competition of 35S-labeled pE3 binding to PKR variants by nonlabeled pE3, pK3, pK3DGYID, eIF2a and VKVIRVDYTKGYID. 35S-labeled pE3,
was synthesized, as described in the legend to Fig. 1, and incubated with Sepharose beads prebound to the appropriate antibodies (see Materials
and Methods), either bound or not bound (beads only) to wild-type PKR or the indicated PKR variants, in the presence or absence of a 503 molar
excess of nonlabeled pE3, pK3, or pK3DGYID, or 1 mM VKVIRVDYTKGYID. Radioactive protein bound was eluted and quantitated as described in the
legend to Fig. 1. INPUT: represents 20% of total 35S-labeled protein used in each assay.
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367–551 overlaps with the region of pK3 and eIF2a in-
teraction and therefore includes the substrate binding
domain (Craig et al., 1996; Kawagishi-Kobayashi et al.,
1997; Sharp et al., 1997). Since we assumed that pE3 is
functionally equivalent to DRBD1 of PKR, it was tempting
to speculate that the homologous regions in PKR, amino
acids 55–75 (DRBD1) could give a similar result. This
hypothesis was tested using the yeast two-hybrid sys-
tem. Table 2 illustrates the interaction of domains in the
amino and carboxyl-termini of PKR. PKR1–296 was found
to interact with PKR367–551. Similarly, PKR1–99 and
PKR1–152, each of which contains DRBD1, interacted not
only with each other and full-length PKR but also with
PKR367–551. This interaction between the regulatory and
catalytic domains of PKR parallels the interaction of pE3
with the PKR367–551 and raises the possibility that in-
teraction between the two halves of PKR may fulfill a
regulatory function.
DISCUSSION
pE3 plays an important role in the ability of vaccinia
virus to grow in interferon treated cells, in part by its
ability to downregulate PKR (Beattie et al., 1991, 1995a;
Chang et al., 1995; Shors and Jacobs, 1997a; Shors et al.,
1997). It has been widely considered that the mechanism
of pE3’s ability to downregulate PKR lies solely in its
capacity to sequester dsRNA. We considered the alter-
native possibility that inhibition of PKR by pE3 could
involve complex formation between the two proteins. The
data presented here demonstrate that pE3 can interact
directly with PKR. A summary of the interactions of pE3
with PKR from both in vitro and in vivo studies is pre-
sented in Fig. 6 and is compared with the interactions of
pK3 with PKR. Clearly, pE3 is capable of direct interaction
with PKR both in vitro and in vivo. The location of sites
within PKR that interact with pE3 have been mapped to
distinct amino- and carboxyl-terminal regions of the ki-
nase. In comparison, pK3 interacts with the substrate
binding domain only. The ability of pE3 to interact with
the amino terminal region of PKR (PKR1–99) is consistent
with the interaction of dsRNA binding regions within
each protein and suggests that pE3 can downregulate
PKR by forming nonfunctional heterodimers. The interac-
tion between pE3 and the DRBD of PKR appears to be
stimulated by dsRNA (Fig. 4) and is equivalent to the
heterodimerization of TRBP to PKR (Cosentino et al.,
1995; Benkirane et al., 1997). A similar interaction under-
lies the ability of pE3 to form homodimers (Table 1 and
Ho and Shuman, 1996b). The molecular basis of the
interaction of pE3 with the substrate binding domain of
PKR is less clear but may resemble a previously undis-
covered interaction between the regulatory and kinase
domains of PKR (Table 2).
The relative importance of these two properties of pE3,
FIG. 5. Effect of dsRNA on the interaction of 35S-labeled pE3 with PKR variants. 35S-labeled pE3, synthesized as described in the legend to Fig. 1,
was incubated with Sepharose beads prebound to the appropriate antibodies (see Materials and Methods), bound to the indicated PKR variants.
Concentrations of poly(I).poly(C) included during immunoprecipitation were as indicated in the figure. Radioactive protein bound was eluted and
quantitated as described in the legend to Fig. 1. INPUT, 20% of total 35S-labeled protein used in each assay.
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the ability to bind dsRNA and the ability to form nonfunc-
tional heterodimers, to the maintenance of an inactive
state of PKR during vaccinia virus infection is not known.
A similar uncertainty exists over the ability of enzymati-
cally inactive variants of PKR to downregulate wild-type
PKR activity in transfected mammalian cells (Clemens
and Elia, 1997). However, in yeast there is evidence
demonstrating that dominant interference by nonfunc-
tional PKR variants involves the formation of defective
heterodimers rather than sequestration of dsRNA (Ro-
mano et al., 1995). Such a mechanism provides a more
effective means for maintaining PKR in an inactive state
because although a small concentration of free dsRNA
can activate PKR, the enzyme is less easily activated
once nonfunctional heterodimers are formed (Romano et
al., 1995). The formation of inactive heterodimers could
provide protection against other cellular mechanisms for
activation of PKR analogous to the activation observed in
vitro by heparin (George et al., 1996).
Although it is clear that the dsRNA binding region of
pE3 is essential for expression of the protein to restore
interferon resistance to E3L-deficient vaccinia virus
(Shors et al., 1997), the genetic dissection of pE3 into
dsRNA binding and dimerization domains has only just
begun. It has been shown that pE3 and PKR bind dsRNA
with comparable affinities (Schmedt et al., 1995; Ho and
Shuman, 1996b). This means that pE3 would need to be
present in a large molar excess of PKR and dsRNA for
the sequestration model to account for PKR downregu-
lation. Such a condition could occur in experiments that
utilize the expression of pE3 from a transgene (Chang et
al., 1995). In vaccinia virus-infected cells, the levels of
pE3 may not be sufficient to sequester all dsRNA acti-
vators, but the formation of nonfunctional heterodimers
TABLE 2
Interaction of PKR Amino- and Carboxy-Terminal Regions
in the Yeast Two-Hybrid System
Fusion proteins
b-
galactosidase
activity a
Fold
increaseb
GAL4-activation
domain
GAL4-DNA binding
domain
No Plasmid No Plasmid 0.06 —
GAL4-AD GAL4-BD 0.06 —
SV40 LT (84-708) Murine p53 (72-390) 3.51 58.5
(Arg296)PKR GAL4-BD 0.047 —
(Arg296)PKR (Arg296)PKR 0.507 10.8
(Arg296)PKR PKR1-99 0.504 10.7
PKR1-152 GAL4-BD 0.047 —
PKR1-152 PKR1-99 1.564 33
PKR1-152 PKR367-551 0.289 6.1
PKR1-152 E3L 0.322 6.8
PKR1-99 GAL4-BD 0.047 —
PKR1-99 PKR367-551 0.307 6.5
PKR1-99 E3L 0.370 7.8
E3L GAL4-BD 0.045 —
E3L PKR367-551 1.32 29.3
PKR1-296 GAL4-BD 0.045 —
PKR1-296 PKR367-551 0.284 6.3
Note. Saccharomyces cerevisiae, strain SFY526, was transfected
with the indicated combination of pGAD-AD and pGBT-BD plasmids
and assessed for the ability to activate IacZ transcription, as described
in Table 1.
a Yeast transfectants were grown in liquid medium and assayed for
b-galactosidase activity as described under Materials and Methods.
Values represent the mean of three experiments for each combination.
b Fold increase over the values obtained from cotransfections con-
taining GAL4-AD (pGAD424) or GAL4-BD (pGBT9) plasmids.
TABLE 1
Interaction of pE3 with PKR Variants
in the Yeast Two-Hybrid System
Fusion proteins
b-
galactosidase
activity a
Fold
increaseb
GAL4-activation
domain
GAL4-DNA binding
domain
No Plasmid No Plasmid 0.09 —
GAL4-AD GAL4-BD 0.09 —
SV40 LT (84-708) Murine p53 (72-390) 6.18 68.7
GAL4-AD (Arg296)PKR 0.07 —
GAL4-AD pE3 0.05 —
pE3 GAL4-BD 0.04 —
pE3 (Arg296)PKR 1.02 11.3
GAL4-AD PKR1-296 0.07 —
pE3 PKR1-296 1.19 13.2
GAL4-AD PKR1-99 0.04 —
pE3 PKR1-99 5.76 64
GAL4-AD PKR99-551 0.08 —
pE3 PKR99-551 1.22 13.5
GAL4-AD PKR367-551 0.08 —
pE3 PKR367-551 7.66 85.1
pE3 pE3 5.63 62.6
GAL4-AD pK3 .05 —
(Arg296)PKR pK3 7.5 125
pK3 PKR1-296 .05 —
pK3 PKR244-551 1.49 24.8
pK3 PKR1-99 .03 —
pK3 PKR367-551 .216 3.6
pK3 pK3 .06 —
Note. Saccharomyces cerevisiae, strain SFY526, was transfected
with the indicated combination of GAL4 activation domain (pGAD-AD)
and GAL4 DNA binding domain (pGBT-BD) plasmids and assessed for
the ability to activate IacZ transcription, as described under Materials
and Methods. Only colonies that contained both plasmids were able to
grow on selective medium plates. These were subsequently grown in
liquid cultures under the same selection conditions and assayed for
b-galactosidase using ONPG as substrate (where 1 ø b-galactosidase
5 1 mmole ONPG hydrolyzed per minute) (Fields and Song, 1989).
Vectors encoding each of the GAL4-fusion proteins only were trans-
formed together or with each PKR mutant as negative controls. Vectors
containing K3L were included as positive controls for interaction with
PKR variants. Similarly, SV40LT(84-708) and p53(72-390) were trans-
formed together as a positive control.
a Yeast transfectants were grown in liquid medium and assayed for
b-galactosidase activity as described under Materials and Methods.
Values represent the mean of three experiments for each combination.
b Fold increase over the values obtained from cotransfections con-
taining GAL4-AD (pGAD424) and GAL4-BD (pGBT9) plasmids.
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with PKR could prevent PKR activation even in the pres-
ence of low concentrations of free dsRNA.
The surprising interaction of pE3 with the carboxyl-
terminus of PKR led us to reexamine the characteristics
of PKR itself. The interaction of PKR1–99 and PKR1–152
with PKR367–551 suggests a novel autoregulatory mech-
anism for PKR, in which the substrate binding domain is
masked by the first 99 amino acids in the absence of
dsRNA. Such an interaction could provide the molecular
mechanism underlying the inactivity of PKR in the ab-
sence of dsRNA. Subsequently, interaction of the amino
terminal region with dsRNA and the amino terminal re-
gion of another PKR molecule could then ‘‘unmask’’ the
substrate binding domain, resulting in both activation of
the kinase and substrate binding. It is known that auto-
regulatory domains exist in other kinases. For instance,
in protein kinase C (PKC) and myosin light chain kinase
(MLCK) the autoregulatory domains resemble the sub-
strate and interact with the substrate binding domain to
prevent kinase activity (House and Kemp, 1987; Pearson
et al., 1988). This form of regulation, directed at the active
site has been termed intrasteric control (Kemp and Pear-
son, 1991). By analogy, we hypothesize that the regula-
tory domain of PKR from amino acids 1–99 binds at, or
near, its own substrate binding site to inhibit kinase
activity.
A model illustrating the regulation of PKR, is outlined in
Fig. 7 and represents an amalgamation of previously
published models (Mathews, 1993; Robertson and
Mathews, 1996) with our new data. In the absence of
dsRNA, PKR is inactive because amino acids in the
dsRNA binding domains interact with and mask the sub-
strate binding domain(s) in a dsRNA-independent man-
ner through protein-protein interaction, depicted as a in
Fig. 7. This is portrayed as occurring via an intramolec-
ular reaction but could just as well occur via an intermo-
lecular reaction between two PKR molecules in which
the DRBD of one PKR molecule interacts with the sub-
strate binding domain of a second PKR molecule. In the
presence of dsRNA, and the absence of pE3, the amino
terminal region of PKR interacts with dsRNA and the
amino terminal region of another PKR molecule, unmask-
FIG. 6. Summary of the interactions of pE3 and pK3 with PKR. Schematic diagrams of the PKR variants analyzed for binding to pE3 and pK3 along
with the in vitro binding and yeast two-hybrid data. The positions of the dsRNA binding domains and third basic domain are indicated within the
regulatory region as filled boxes. The catalytic region containing the conserved kinase subdomains is indicated as a hatched box. Numbers indicate
amino acid residue. The regions of binding within PKR for pE3 (dark gray) and pK3 (light gray) are indicated. NT, not tested.
309E3L GENE PRODUCT INTERACTS WITH TWO REGIONS IN PKR
ing the substrate binding domain to yield the active form
of the kinase, a dsRNA-bound dimer (depicted as e in
Fig. 7). In the absence of dsRNA, pE3 is able to interact
with the substrate binding domain in the carboxyl-termi-
nal region of PKR maintaining, or stabilizing, an inactive
PKR conformation, depicted as b in Fig. 7. The mainte-
nance of this inactive conformation may, or may not, also
involve domains in the amino-terminal region of PKR. In
the presence of dsRNA, the interaction of pE3 with the
substrate binding domain is reduced, but pE3 is still able
to inhibit PKR activity by forming a nonfunctional het-
erodimer with PKR through the respective dsRNA bind-
ing regions (depicted as c in Fig. 7) or by sequestering
dsRNA (depicted as d in Fig. 7). In the presence of higher
concentrations of dsRNA, sufficient dsRNA remains free
to activate PKR (depicted as e in Fig. 7). The above model
accounts for the characteristics of pE3 and also provides
an explanation of why PKR is inactive in the absence of
dsRNA. The model suggests that pE3 is capable of
downregulating PKR by three distinct mechanisms and
that the relative levels of PKR, pE3, and dsRNA will
determine which mechanism is the most significant un-
der different physiological conditions, as will the pres-
ence of non-dsRNA activators of PKR, such as heparin.
The model is consistent with data presented here, as
well with an accumulation of reported data. It is consis-
tent with data from the reticulocyte cell-free translation
system, showing that increasing the level of pE3 shifts
the dsRNA activation curve (Jagus and Gray, 1994). It is
also consistent with the ability of some variants of PKR
that show little ability to bind dsRNA to retain the ability
to form dimers (Patel et al., 1996) as well as with the
constitutive activity of PKR228–551 (Wu and Kaufman,
1996).
Our data suggests that pE3 and the amino-terminal of
PKR compete for binding to a carboxyl-terminal domain
that overlaps the substrate binding domain, and this
hypothesis is currently being tested. A prediction from
our model is that pE3 should downregulate the activity of
the constitutively active variant PKR228–551. However, it
has been shown that transient coexpression of pE3 is
not able to inhibit PKR228–551 transiently expressed in
COS-1 cells, although the relative levels of each protein
were not determined and colocalization was not demon-
strated (Wu and Kaufman, 1997). The demonstration of
colocalization is important because in vaccinia virus-
infected cells, ,10% of the cellular pE3 pool is cytoplas-
mic (Yuwen et al., 1993). Alternatively, the inability of pE3
expression to downregulate PKR could reflect the need
for pE3 to interact with both amino and carboxy domains
to maintain PKR in an inactive state.
The interaction of pE3 with the carboxyl-terminal do-
main of PKR may also provide vaccinia virus with pro-
tection from the activation of PKR by other mechanisms.
For instance, it is known that heparin can also activate
PKR by interaction with regions that are distinct from the
dsRNA binding domains (Patel et al., 1994; George et al.,
1996). The interaction of pE3 with the substrate binding
domain of PKR could prevent the activation of PKR by
heparin or other cellular activators such as PACT (Patel
and Sen, 1998) and thus could be essential for multipli-
cation of the virus. Recent studies from Romano et al.
have also shown a direct interaction between pE3 and
both the amino-terminal and carboxyl-terminal regions of
PKR (Romano et al., 1995). In addition, these studies
indicate that the interaction of pE3 with PKR involves
both the DRBD of pE3 as well as a domain in the
amino-terminal region of pE3 that is not involved in
dsRNA binding. The importance of the amino-terminal
region of pE3 is also highlighted by a comparison of the
sequence of pE3 with the orf virus OV20.0L gene product,
known to confer interferon resistance (Haig et al., 1998).
The OV20.0L gene product is a pE3 homolog that func-
FIG. 7. Model for the interaction of pE3 with PKR and the dsRNA-
dependent dimerization and activation of PKR. The DRBDs of PKR are
indicated by the number 1 or 2, for DRBD1 and DRBD2, respectively.
The hatched box represents the substrate binding domain. The model
begins with a depiction of PKR in its inactive state, showing the
interaction of the regulatory domain masking the substrate binding
domain (a). This is depicted as occurring via an intramolecular reaction
but could just as well occur via an intermolecular reaction between two
PKR molecules giving an inactive dimer. The model goes on to show
that pE3 can prevent PKR activation by three different mechanisms: in
the absence of dsRNA by interaction with the substrate binding domain
(b) and by the formation of nonfunctional heterodimers formed by three
different mechanisms (c): in the absence of dsRNA by interaction with
the substrate binding domain (b); by the formation of nonfunctional
heterodimers formed by interaction with dsRNA and the DRBDs of PKR
(c); and by sequestration of dsRNA (d). The active form of PKR is
depicted in e.
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tions in vitro to downregulate PKR. This protein shows
weak homology to pE3 in the dsRNA binding domain but
has a perfectly conserved PPRWF motif in the amino-
terminal region.
The interaction of PKR1–99 and PKR1–152 with
PKR367–551, which suggests a novel autoregulatory
mechanism for PKR, has been anticipated to some extent
by prior studies. Similarly, other investigators have con-
cluded that multiple domains within PKR contribute to
PKR-PKR interactions. The most significant previous ob-
servation is that PKR228–551 is constitutively active,
which led to the proposition that the amino-terminal
region contains sequences that inhibit kinase activity
(Wu and Kaufman, 1997). In addition, Patel et al., using
hexahistidine-tagged full-length PKR bound to Ni21-
charged Sepharose, concluded that PKR-PKR interaction
involves at least two PKR binding domains that function
independently and which lie in the amino- and carboxyl-
terminal regions, respectively (Patel et al., 1995). Simi-
larly, Dever et al. have inferred multiple domain interac-
tions from their demonstration of a direct interaction
between PKR and a baculovirus gene product, PK2, that
resembles the kinase domains V-XI of PKR (Dever et al.,
1998). In contrast to our results, Wu et al. were unable to
demonstrate an interaction between (Arg296)PKR and
PKR1–123 transiently expressed in vivo, but may have
been working below the limit of detection in their assay
(Wu and Kaufman, 1996). Similarly, these authors were
unable to demonstrate dimerizaton between PKR1–123
and PKR99–551 in vivo although this could reflect the
presence of sequences inhibitory to interaction of the
amino- and carboxyl-terminal domains by sequences
between amino acids 123–367.
Our results demonstrate for the first time that pE3 can
interact with a region in the carboxyl-terminal region of
PKR, that is the same as, or overlaps with, the substrate
binding domain, in a dsRNA-independent manner. Our
results have led to a testable model for the regulation of
PKR by dsRNA and have also underlined the continued
usefulness of viral regulators as tools to dissect the
mechanisms regulating PKR activity.
MATERIALS AND METHODS
35[S]methionine (1000 Ci/mmol) was purchased from
Dupont/NEN (Boston, MA). Restriction enzymes, and
transcription and translation systems were from Pro-
mega Corporation (Madison, WI). All other reagents were
of ACS grade or better and purchased from either Sigma
Biochemicals (St. Louis, MO) or Fisher Scientific (Pitts-
burgh, PA) unless otherwise stated. Hela CCL2 were
purchased from ATCC (Rockville, MD).
pTM1 plasmid constructs
The construction of pTM1K3L has been described
(Carroll et al., 1993; Jagus and Gray, 1994). pTM1 inserts
the 59UTR of EMCV upstream of the open reading frame
to produce a transcript that is translated efficiently in
vitro in a cap-independent fashion (Moss et al., 1990).
cDNA for E3L was transferred into pTM1 from pHY26
(Yuwen et al., 1993), kindly supplied by Dr. Bernard Moss.
Yeast two-hybrid plasmid constructs
For the yeast two-hybrid assay E3L, K3L, and PKR
variants (Arg296)PKR, des-(297–551)-PKR (PKR1–296),
and des-(1–241)-PKR (PKR242–551), were cloned into the
vectors pGAD424 and pGBT9 (Clontech) to create fusion
proteins with the GAL4-activation domain (AD) and the
GAL4-DNA binding domain (BD) domain, respectively.
The plasmids pGAD424E3L and pGBT9E3L were con-
structed by digesting the E3L cDNA from pET11dE3L
(Jagus and Gray, 1994) with EcoRI/BamHI and subcloning
this fragment into similarly digested pGAD424 and
pGBT9 vectors. The construction of pGAD424K3L and
pGBT9K3L has been described (Sharp et al., 1997). The
PKR variants (Arg296)PKR, PKR1–296, and PKR242–551
in pGAD424(AD) and pGBT9(BD) were a gift from Dr.
Michael Katze, and their construction has been de-
scribed (Gale et al., 1996). The mutant des-(100–551)-PKR
(PKR 1–99) was constructed by restriction digestion of
pGBT9(Arg296)PKR with NcoI/BamHI to remove part of
the cDNA encoding amino acids 99–551, followed by
ligation using an NcoI/BamHI adaptor. The mutant des-
(1–98)-PKR (PKR99–551) was constructed by subcloning
an NcoI/BamHI fragment from pGBT9(Arg296)PKR into
pGBT9(NcoI) digested with NcoI/BamHI. The mutant
des-(1–366)-PKR (PKR367–551) was constructed by de-
letion of an EcoRI fragment encoding amino acids 1–366.
pGEX4T plasmid constructs
For production of GST-fusion proteins for in vitro bind-
ing, pGEX4T-1(NcoI) and pGEX4T-1(NdeI) were con-
structed by the insertion of an NcoI or NdeI linker within
the SmaI site of the polylinker of pGEX4T-1 (Pharmacia).
cDNA encoding (Arg296)PKR was obtained from
pGBT9(NcoI) following digestion with NcoI/SalI and in-
serted into NcoI/XhoI digested pGEX4T-1(NcoI) to create
pGEX 4T-1(NcoI)(Arg296)PKR. To create PKR1–99 in
pGEX4T-1, an NdeI/SalI cDNA fragment from pGBT9
PKR1–99 was subcloned into similarly digested pGEX4T-
1(NcoI) vector. PKR99–551 in pGEX4T-1(NcoI) was con-
structed by subcloning an NcoI/SalI cDNA fragment en-
coding PKR amino acids 99–551 from pGBT9(NcoI)-
PKR99–551 into the NcoI/XhoI site of pGEX4T-1(NcoI).
des-(524–551)-PKR (PKR1–523) was constructed from
pGAD424(Arg296)PKR by digestion with Bsu 36I/BamHI,
followed by digestion with Klenow fragment (Promega)
and re-ligation. This encodes a protein with a deletion of
the carboxyl-terminal 28 amino acids. The cDNA encod-
ing PKR1–523 was removed from pGAD424PKR1–523 by
digestion with NdeI and subcloned into pGEX4T-1(NdeI).
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All DNA constructs were sequenced using the Perkin-
Elmer dye termination cycle sequencing ready reaction
kit together with the Applied Biosystems 373 DNA se-
quencer.
Production of recombinant proteins
The pET11a (Novogen) constructs containing PKR mu-
tants (Arg296)PKR, des(361–366)-PKR (PKRD6), and
PKR242–551, have been described previously (Barber et
al., 1991). The PKR variants were produced in the E. coli
strain, BL21(DE3)pLysS, essentially as described (Barber
et al., 1995). Recombinant pE3, pK3, and des(75–78)-pK3
(pK3DGYID) were expressed and purified as described
(Carroll et al., 1993; Jagus and Gray, 1994; Sharp et al.,
1997).
Glutathione S-transferase (GST) and GST-fusion pro-
teins were generated from pGEX4T-1, or pGEX4T-1 con-
structs, in the E. coli strain BL21. Overnight cultures of
BL21 harboring the relevant pGEX4T-1 clone were in-
duced with 100 mM isopropylthiogalactopyranoside for
3 h and extracts prepared essentially as described
(Smith and Johnson, 1988) except that cells were resus-
pended in lysis buffer (50 mM HEPES, pH 7.5; 150 mM
NaCl; 1 mM DTE; 20 mg/ml aprotinin; 10 mg/ml leupeptin;
20 mg/ml chymostatin; 1 mM phenylmethylsulfonylfluo-
ride (PMSF); 1 mM EGTA; 0.1 mM EDTA; and 0.1% Triton
X-100) prior to sonication.
In vitro binding assays
Two types of in vitro binding assays were used. In the
first, binding of proteins to PKR was assessed by their
ability to bind to immunopurified PKR. This assay was
used for in vitro binding assays involving native PKR and
recombinant PKR variants. In the second, binding was
assessed by co-recovery of 35S-labeled proteins with
GST-tagged PKR using glutathione–Sepharose beads
(GST–glutathione–Sepharose binding assay). This was
used for in vitro binding assays involving GST-tagged
recombinant PKR variants.
In vitro binding assay using native and recombinant
PKR
35S-labeled pE3 and pK3 were synthesized in a cou-
pled transcription/translation system (TNTQuick, Pro-
mega Corporation) containing 35[S]methionine (500 mCi/
ml). The 35S-labeled proteins were used in binding as-
says with native PKR and the recombinant variants
(Arg296)PKR, PKRD6, and PKR1–296 bound to anti-PKR
monoclonal antibody (mAB) [provided by Dr. Ara Hovan-
essian, Pasteur Institute, Paris, France (Laurent et al.,
1985)] covalently bound to Sepharose beads (Black et al.,
1989). Binding reactions were performed essentially as
described in (Sharp et al., 1997) but with the inclusion 1
mg/ml of soybean trypsin inhibitor in all binding and
wash buffers. Similar binding assays were performed
using recombinant PKR242–551 and anti-PKR polyclonal
antibody bound to protein-G agarose, as described pre-
viously (Barber et al., 1991). All binding experiments in-
cluded a control without PKR, but with the relevant anti-
body bound to beads (beads only controls). The volume
of beads used reflected the minimum needed to recover
.95% of PKR without giving high backgrounds of non-
specific binding. Bound proteins were eluted in SDS–
PAGE sample buffer and analyzed by SDS–PAGE using a
Tris-Tricine buffer system as described previously
(Schagger and von Jagow, 1987). 35S-labeled protein was
visualized using the Storm 840 Phosphoimager (Molec-
ular Dynamics Inc., Sunnyvale, CA) and band intensity
was quantified using Image-Quant software (Molecular
Dynamics Inc. Sunnyvale, CA).
In vitro GST–glutathione–Sepharose binding assay
Bacterial cell extracts containing GST-fusion pro-
teins were prepared as described above. For the anal-
ysis of protein interactions, 100 ml cell extract (approx-
imately 1 mg protein) was incubated with 25 ml of
glutathione–Sepharose beads (50% suspension in
binding buffer) in 50 mM HEPES, pH 7.5; 150 mM NaCl;
1 mM DTE; 20 mg/ml aprotinin; 10 mg/ml leupeptin; 20
mg/ml chymostatin; 1 mM phenylmethylsulfonylf-
louride (PMSF); 1 mM EGTA; 0.1 mM EDTA; 0.1% Triton
X-100; and 1 mg/ml soybean trypsin inhibitor, in a final
volume of 400 ml and incubated with rotation at 4°C for
2 h. The beads were washed three times with 1 ml
binding buffer and resuspended in 200 ml binding
buffer. A TNTQuick reaction mix containing 35S-la-
beled protein (10 ml) was added. The mixture was
incubated for 1 h with rotation at 4°C. The beads were
washed five times with 1 ml wash buffer (the same as
binding buffer except for 400 mM NaCl and 0.5% Triton
X-100). The glutathione–Sepharose beads were resus-
pended in 23 SDS–PAGE sample buffer, incubated at
95°C for 5 min and subjected to 17.5% SDS–PAGE
using a Tris–Tricine buffer system, as above. 35S-la-
beled protein was visualized and quantified using the
Storm 840 Phosphoimager and Image-Quant software
(Molecular Dynamics Inc., Sunnyvale, CA).
Western blot analysis of GST-fusion proteins
BL21 cell extracts containing GST or the GST-fusion
protein were subjected to 12.5% SDS–PAGE (Jagus,
1987), transferred to Immobilon-P and blocked with
BLOTTO (Johnson et al., 1984) for 1 h at 4°C. Blots were
probed with goat anti-GST polyclonal antibody (1 h at
4°C), followed by rabbit anti-goat HRP-conjugated anti-
body (1 h at 4°C). Specific GST-fusion products were
detected using the Amersham ECL kit as per manufac-
turer’s recommendations.
312 SHARP ET AL.
Yeast two-hybrid assay system
The Saccharomyces cerevisiae strain SFY526 was
transformed using the lithium acetate method (Gietz et
al., 1992) with the indicated combination of GAL4 activa-
tion domain, pGAD (AD), and GAL4 DNA binding domain
pGBT (BD), plasmids. Only colonies that contained both
plasmids were able to grow on SD-agar plates supple-
mented with leucine and tryptophan. Single colonies
were picked and grown overnight in liquid SD medium
containing the same amino acids followed by growth in
nonselective medium for 3 h and assayed for b-galacto-
sidase using o-nitrophenyl b-D-galacto-pyranoside
(ONPG) as substrate (where 1 U b-galactosidase 5 1
mmole ONPG hydrolyzed per minute) (Fields and Song,
1989).
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